Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2013

Araya Tomoyuki, Kasahara Kazuo, Demura Yoshiki, Matsuoka Hiroki, Nishitsuji Masaru, Nishi Koichi

Abstract excerpt

Neutropenia is a rare side effect of gefitinib and was scarcely reported in many large-scale randomized phase III trials using gefitinib monotherapy as first-line treatment. A 77-year-old female was referred to our institution due to abnormal shadow of the right lung, diagnosed by CT scan and bio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Neutropenia

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 23489558
DOI: 10.1016/j.lungcan.2013.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23489558-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.PMID 23489558Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.Semantic proximity Read ↗

Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report.Semantic proximity Read ↗

Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.Semantic proximity Read ↗

Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib.Semantic proximity Read ↗

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR- TKI-induced grade 3 stomatitis and interstitial lung disease: a case reportSemantic proximity Read ↗

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).Semantic proximity Read ↗

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.Semantic proximity Read ↗

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.Semantic proximity Read ↗

Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.